Frazier boosts next pure-play biotech fund to $419M, readies new bets for a practiced strategy
Jamie Topper Frazier Healthcare Partners
The money in biotech keeps getting bigger.
After Frazier Healthcare Partners closed its first dedicated biotech fund with $262 million almost exactly two years ago, managing general partner Jamie Topper and his crew of VC specialists went after some 16 to 18 new biotech investments, hewing to the startup rounds that are their sweet spot — and which accounts for the bulk of the cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.